Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by proposed guidelines for systematically dealing with the toxicities of these drugs.
Breast cancer patients who have radiotherapy targeted at the original tumor site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results.
A ground-breaking new class of oral drugs for treating breast cancer, known as cyclin-dependent kinase (CDK) inhibitors, are generally well-tolerated, with a manageable toxicity profile for most patients. This is the conclusion of a comprehensive review of toxicities and drug interactions related to this class of drugs.
Sometimes a big idea begins as something small, coming when you least expect it and tacked on as a sort of hobby, playing second fiddle to your main event. Whether starting in the kitchen or dorm room, these ten brands grew in unexpected ways, surprising their founders as they became multi-million dollar companies. Here, ten women who created and built amazing companies on the side—proof that the best concepts can come when you’re pursuing something else.